|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1996-9-9
|
|
pubmed:abstractText |
Levosimendan in a new inodilator drug that sensitizes troponin C in heart muscle cells to calcium, thus improving contractility. In previous studies, a single 2 mg intravenous dose of levosimendan increased cardiac output (CO) in healthy volunteers by about 40% and decreased pulmonary capillary wedge pressure in heart failure patients by 40-50%. The aim of the present, double-blind study was to evaluate the safety of concomitant use of levosimendan and an ACE-inhibiting drug.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0031-6970
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
451-8
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8706769-Adult,
pubmed-meshheading:8706769-Aged,
pubmed-meshheading:8706769-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:8706769-Blood Pressure,
pubmed-meshheading:8706769-Captopril,
pubmed-meshheading:8706769-Cardiac Output,
pubmed-meshheading:8706769-Cardiotonic Agents,
pubmed-meshheading:8706769-Cross-Over Studies,
pubmed-meshheading:8706769-Double-Blind Method,
pubmed-meshheading:8706769-Drug Interactions,
pubmed-meshheading:8706769-Echocardiography,
pubmed-meshheading:8706769-Electrocardiography, Ambulatory,
pubmed-meshheading:8706769-Half-Life,
pubmed-meshheading:8706769-Heart Failure,
pubmed-meshheading:8706769-Heart Rate,
pubmed-meshheading:8706769-Hemodynamics,
pubmed-meshheading:8706769-Humans,
pubmed-meshheading:8706769-Hydrazones,
pubmed-meshheading:8706769-Injections, Intravenous,
pubmed-meshheading:8706769-Male,
pubmed-meshheading:8706769-Middle Aged,
pubmed-meshheading:8706769-Myocardial Contraction,
pubmed-meshheading:8706769-Pyridazines
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
|
|
pubmed:affiliation |
Orion-Farmos, Espoo, Finland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
